JNJ J&J's strong drug pipeline (icotrokinba, Tremfya) and strategic business spin-off position it for accelerated growth, making it an attractive long-term investment.However, it is not currently in my portfolio.
JNJ Beat the estimates LOL: J&J prezi s203.q4cdn.com/636242992/files/doc_financials/2025/q1/Final-JNJ-Earnings-Presentation-Q1-2025-Webcast.pdf showed it could grow operationally despite headwinds and beat bottom-line estimates, the report highlights the major challenge posed by the Stelara patent cliff and ongoing pressures in parts of its MedTech business. Therefore, it's not "good" because of these significant challenges clouding future performance, particularly the accelerating impact of Stelara biosimilars throughout 2025. Plus Orthopaedics division declined, and Negative impacts from foreign exchange rates and of course Gross profit margin decreased compared to the previous year. This means beat in the premarket newsflow.
JNJ Wow a phony lawsuit by Texas, I'll be looking for a buy position, Thanks poorly educated maga! 😆
